HEALTH● LOW2h ago · Sep 21, 2026, 3:43 PM
J&J sees positive late-stage data for Caplyta in reducing bipolar manic symptoms
Seeking Alpha Tech · global
Johnson & Johnson has reported positive results from late-stage clinical trials for Caplyta, indicating its effectiveness in reducing bipolar manic symptoms. This could lead to a new treatment option for bipolar disorder.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH33m agoTamil Nadu government hospitals running short of critical medicines for pre-term babiesThe HinduHEALTH39m agoTag : 988 _ lifelinenewsroomamerica.com · United StatesHEALTH39m agoRecognizing early signs of Alzheimer and Dementia on World Alzheimer Daykatu.com · United StatesHEALTH53m agoMumps outbreak at California college linked to student athletesThe Independent World